Abstract
Eosinophilic esophagitis (EoE) is a relatively recently identified but now frequently encountered antigen/immune-mediated disease which places significant burden on patients and the healthcare system. With its growing prevalence and recognition by healthcare providers in multiple disciplines, substantial progress has been made regarding the diagnostic criteria, clinical evaluation, tools for disease assessment, and immune pathways related to pathogenesis. Current treatment goals focus on the amelioration of inflammation and prevention of remodeling consequences using proton pump inhibitors, swallowed topical steroids, elimination diets, and esophageal dilation. Ongoing research holds promise for more efficacious and targeted therapies as well as a personalized approach to the care of patients with EoE.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 183-197 |
| Number of pages | 15 |
| Journal | Annual review of medicine |
| Volume | 72 |
| DOIs | |
| State | Published - Jan 27 2021 |
Funding
Dr. Nirmala Gonsalves serves on the advisory board for Allakos and receives royalties from Up to Date. Dr. Ronak V. Patel has nothing to disclose. Dr. Ikuo Hirano has served as a consultant for Adare, Allakos, Arena, AstraZeneca, EsoCap, Gossamer, Receptos, Regeneron, and Shire Pharmaceuticals. He has received research funding from Adare, Allakos, Receptos, Regeneron, and Shire Pharmaceuticals.
Keywords
- Eosinophilic esophagitis
- dysphagia
- eosinophilic gastrointestinal disease
- esophageal dilation
- esophageal stricture
- gastroesophageal reflux disease
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology